FDA approval for Rocket gene therapy (LAD 1) The FDA approved Rocket gene therapy for severe leukocyte adhesion deficiency type 1 (LAD 1), an ultra rare disease characterized by vulnerability to serious infections. The approval is significant because gene the…
What’s the FDA status of the Rocket gene therapy? #health
The FDA approved Rocket Pharmaceuticals' gene therapy for severe leukocyte adhesion deficiency type 1 (LAD 1), marking a significant advancement for ultra-rare disease treatment. This approval affects patients with LAD 1, a life-threatening condition, and healthcare systems integrating genetic therapies. No direct cybersecurity vulnerabilities are associated with this approval.